Stockwinners Market Radar for November 09, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EST Cathie Wood's ARK Investment bought 476K shares of Personalis today

19:50 EST Xyratex Ltd. trading halted, news pending

18:54 EST Walgreens Boots Alliance sells shares of Cencora for $674M - Walgreens Boots Alliance (WBA) announced that it has sold shares of Cencora (COR) common stock pursuant to variable prepaid forward transactions executed in reliance on Rule 144 under the Securities Act of 1933, as amended, for current proceeds of approximately $424 million and, depending on the stock price at the time, potentially additional proceeds at maturity. In addition, and subject to the closing of the Rule 144 transaction, Walgreens Boots Alliance entered into a concurrent share repurchase by Cencora for proceeds of approximately $250 million. Walgreens Boots Alliance's ownership of Cencora's common stock has decreased as a result of the concurrent share repurchase by Cencora but remains at approximately 15%. The Company intends to use the proceeds primarily for debt paydown and general corporate purposes. The transaction is another decisive action to further simplify the Company's portfolio, while improving cash management.

18:51 EST SoFi Technologies CEO buys $298K in common stock - In a regulatory filing, SoFi Technologies disclosed that its CEO Anthony Noto bought 44K shares of common stock on November 9th in a total transaction size of $298K.

18:42 EST Clearwater Paper temporarily suspends certain operations in Idaho - Clearwater Paper reported that it temporarily suspended certain manufacturing operations at its Lewiston, Idaho facility. An incident impacting the regional natural gas system has resulted in the disruption of natural gas deliveries to the mill and the surrounding areas. "We are focused on the safety of our employees and maintaining our assets while we wait for repairs on the gas pipeline to be completed," said Arsen Kitch, president and chief executive officer. "We expect to resume the impacted operations in the coming days."

17:29 EST Illumina down 7% at $99.20 after Q3 results, FY23 guidance cut

17:27 EST Banco Itau Chile announces termination of American Depositary Shares program - Banco Itau Chile announced that The Bank of New York Mellon, as depositary issued a notice to the holders of American Depositary Shares representing common shares of the company terminating the American Depository Receipt program according to the requirements under the Amended and Restated Deposit Agreement dated as of June 11, 2018 among the company, the depositary, and owners and holders from time to time of ADSs issued thereunder. The ADR program and the deposit agreement will be terminated on February 5, 2024.

17:20 EST Murphy USA director sells $11.0M in common stock - In a regulatory filing, Murphy USA disclosed that its director Robert Murphy sold 30K shares of common stock on November 8th in a total transaction size of $11.0M.

17:16 EST Lyell Immunopharma announces Orphan Drug Designation for LYL845 - Lyell Immunopharma announced that the FDA granted Orphan Drug Designation to LYL845, an investigational tumor infiltrating lymphocyte, or TIL, product candidate for the treatment of patients with stage IIB-IV melanoma.

17:12 EST Autoliv raises quarterly dividend by 3% to 68c per share - The dividend will be payable on Wednesday, December 13, 2023 to Autoliv shareholders of record on the close of business on Tuesday, November 28.

17:06 EST Pennsylvania American Water receives PPUC approval for BASA deal - Pennsylvania American Water, a subsidiary of American Water, received approval from the Pennsylvania Public Utility Commission to purchase the Butler Area Sewer Authority wastewater system for $230M. The approval follows a settlement agreement reached in August between the Office of Consumer Advocate, Office of Small Business Advocate, and Bureau of Investigation and Enforcement of the PUC. The settlement agreement approved today will significantly expand the company's assistance programs to further address affordability. As part of the agreement, Pennsylvania American Water will nearly double its shareholder contribution to the hardship grant program, increasing the fund by $3.5 million over five years. The agreement also expands the program's income eligibility criteria from 200 to 250 percent of Federal Poverty Income Guidelines, resulting in an estimated 52,900 additional water and 8,800 additional wastewater customers being eligible to receive bill assistance grants. The agreement also benefits commercial customers by establishing a payment arrangement program for commercial customers - previously only available to residential customers.

17:04 EST Unity not providing Q4 or FY23 guidance - The company states: "Several weeks ago, we started a comprehensive assessment of our product portfolio to focus on those products that are most valuable to our customers. We are also evaluating the right cost structure that aligns with the more focused portfolio. We are acting quickly and expect to make final decisions over the next few weeks. We expect to start implementing the plan within this quarter and expect to complete all interventions before the end of the first quarter of 2024. This will likely include discontinuing certain product offerings, reducing our workforce, and reducing our office footprint. The exact timing of these interventions is difficult to estimate. We are therefore not providing guidance for the fourth quarter or the full year 2023. We will provide guidance for 2024 with our fourth quarter and full year 2023 results. At that time, we will also share more details on our operational interventions, which are expected to gradually improve our results."

17:03 EST Unity CEO says company has significant opportunity to accelerate revenue growth - Jim Whitehurst, Interim CEO, stated: "After a month at Unity, I believe that our key product, the Unity Engine, is unique and a foundation upon which the game industry was built. I also believe that the combination of Unity and ironSource provides us with the assets, capabilities and data to enable our customers to successfully build and scale their businesses. And I am impressed by the people at Unity, some of the brightest and most passionate in tech. This leads me to believe that we have a significant opportunity to accelerate revenue growth, improve profitability metrics and increase free cash flow generation going forward. However, we are currently doing too much, we are not achieving the synergies that exist across our portfolio, and we are not executing to our full potential. We aim to address these opportunities to emerge as a leaner, more agile, and faster growing company. We will share specifics as plans are finalized over the next few months."

17:03 EST Sana: FDA clears IND to study SC291 for B-cell mediated autoimmune diseases - Sana Biotechnology announced the U.S. Food and Drug Administration FDA has cleared the company's Investigational New Drug IND application to initiate a study of SC291 in patients with multiple B-cell mediated autoimmune diseases, including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody ANCA -associated vasculitis.Our goal is to develop SC291 for patients with multiple B-cell mediated autoimmune diseases, and the clearance of this IND is an important milestone," said Doug Williams, PhD, Sana's President of Research and Development. "SC291 is an allogeneic CAR T cell therapy with a scaled manufacturing process that produces hundreds of patient doses per manufacturing run, which we believe will be critical to addressing these large unmet needs. The use of allogeneic cells further simplifies the treatment paradigm for doctors and patients alike by eliminating apheresis and individualized patient-by-patient manufacturing of the drug product. We intend to begin treating patients in the near-term and expect to disclose initial safety and efficacy data across multiple diseases in 2024."

16:51 EST Vor Bio presents 'positive' data update on trem-cel - Vor Bio presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel in patients with acute myeloid leukemia, AML. "With this additional hematologic protection data in multiple patients over multiple doses of Mylotarg, we are now seeing the promise of our approach come to light as a potential next-generation therapeutic option for AML patients," said Eyal Attar, MD, Vor Bio's Chief Medical Officer. "Now with VCAR33ALLO in the clinic, we have the potential for an even better combination with trem-cel with the goal of providing durable responses or even a potential cure for AML." "The results being presented further validate Vor Bio's platform and approach. We are excited to see that trem-cel has worked as expected in these patients, providing them with hematologic protection and exposing their leukemia to targeted therapy," said Dr. Guenther Koehne.

16:46 EST Babcock & Wilcox sees FY24 adjusted EBITDA $100M-$110M

16:38 EST Savers Value Village authorizes up to $50M share repurchase program - Savers Value Village announced the authorization of a share repurchase program of up to $50 million of the Company's common stock. Under the program, Savers may purchase shares from time to time in compliance with applicable securities laws, that may include Securities Act Rule 10b-18. The timing and amount of any shares purchased will be based upon a variety of factors, including the share price of the common stock, general market conditions, alternative uses for capital, Savers' financial performance, and other considerations. The share repurchase program does not obligate Savers to purchase any minimum number of shares, and the program may be suspended, modified, or discontinued at any time without prior notice. Any repurchases will be funded by available cash and cash equivalents.

16:35 EST Hamilton Beach announces $25M stock repurchase program - The Board of Directors approved a stock repurchase program providing for the purchase of up to $25M of the company's outstanding Class A Common Stock effective January 1, 2024 and running through December 31, 2025. The company's previously authorized share buyback program was approved by the Board of Directors on February 22, 2022 for the purchase of up to $25M of the company's outstanding Class A common stock through December 31, 2023. Under the company's previously authorized share buyback program, through September 30, 2023 the company has repurchased a total of 400,698 shares for a total aggregate purchase price of $4.5M.

16:35 EST Victory Capital reports AUM of $148.9B as of October 31 - Victory Capital reported assets under management of $148.9 billion as of October 31, 2023, and average assets under management for October of $151.3 billion.

16:32 EST Invesco reports preliminary AUM $1.45T as of October 31 - A decrease of 2.5% versus previous month-end. The firm experienced net long-term outflows of $0.1B in the month. Non-management fee earning net inflows were $1.7B and money market net outflows were $10.9B.

16:31 EST NVR announces $750M share repurchase plan - NVR announced that its Board of Directors has authorized the repurchase of up to an aggregate of $750M of its outstanding common stock. The repurchase authorization does not have an expiration date.

16:29 EST AllianceBernstein reports preliminary AUM $652B as of October 31 - Down from $669B at the end of September. The 2.5% AUM decrease was primarily due to market depreciation, coupled with net outflows. By channel, Institutions and Private Wealth experienced net outflows while Retail net flows were flat in October.

16:28 EST Granite Ridge raises FY23 annual production view to 22.5K-24K from 21.5K-23K

16:22 EST Bolt Biotherapeutics sees cash funding operations, milestones through 2025

16:20 EST Expeditors announces listing transfer to NYSE - Expeditors International of Washington announced that it is transferring the listing of its common stock to the New York Stock Exchange from the Nasdaq Stock Market LLC. Expeditors' common stock is expected to begin trading on the NYSE on Tuesday, November 21, 2023, and will continue to be traded under its current ticker symbol "EXPD." Expeditors' common stock is expected to continue to trade on Nasdaq until the close of the market on Monday, November 20, 2023.

16:17 EST MarketAxess CFO Gerosa to step down - MarketAxess Holdings announced that its Chief Financial Officer, Christopher N. Gerosa, will step down, effective January 31, 2024, to accept a position at a private company that provides technology solutions within the commercial bank sector. A formal search process for the selection of a new Chief Financial Officer has been initiated by the company. "On behalf of the Board of Directors and the leadership team, I want to thank Chris for his leadership of the finance organization over the last several years, and we wish him all the best in his next role," said Chris Concannon, MarketAxess CEO.

16:06 EST Akili sees cash, equivalents sufficient to fund operations into 2H25

16:04 EST Vuzix says outlook 'remains positive' into 2024 - Our overall outlook for the remainder of 2023 and into 2024 remains positive. We have a strong book of business with identified opportunities, representing large potential deals and cornerstone customers for our enterprise products. And on the OEM products and services side of our business, we expect to enter into new projects with new and existing defense and consumer product focused customers over the course of the coming months," said CEO Travers. "Vuzix' business has reached a point to where we have both the ability and need to realign certain parts of the organization to take advantage of scale and realign our operations to better serve our customers. As a result, we are making changes that are expected to lower operating costs by as much as 20% annually once fully implemented. The process is underway and will continue into 2024. It impacts everything from operations to product development as well as marketing and sales. We expect these adjustments will not only better support our growing customer base in all parts of our business but also extend our operational runway and improve enterprise product margins. We have a bullish stance on the future, and we are focused on realigning our company to become more efficient, lower our cash operating burn and put ourselves on a faster and more visible path to profitability," concluded Travers.

15:55 EST Takeda says FDA approves ADZYNMA - Takeda announced that the U.S. Food and Drug Administration has approved ADZYNMA for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura. ADZYNMA is the first and only FDA-approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme. "People living with cTTP face serious, life-threatening health challenges, and until today, were without any approved treatment specifically indicated for their disease," said Julie Kim, president, U.S. Business Unit and U.S. country head at Takeda. "As we strive to help patients with limited or no treatment options, developing innovative treatments in rare diseases is an inspiring challenge and one we have taken on for 70-plus years as a leader in hematology. Today, we are proud to further support the rare disease community by delivering ADZYNMA as the first FDA-approved therapeutic option for people with cTTP."

15:31 EST Marriott increases share repurchase authorization by 25M shares - Marriott International announced that its board of directors declared a quarterly cash dividend of 52c per share of common stock. The dividend is payable on December 29, to shareholders of record as of the close of business on November 22. The company also announced that its board has increased the authorization to repurchase the company's Class A common stock by an additional 25M shares, which are in addition to the approximately 7.3M shares that remained available as of October 31 for repurchase under prior authorizations. Year-to-date through October 31, the company has repurchased 18.3M shares for $3.3B.

14:37 EST OpenAI introduces Data Partnerships to produce datasets for training AI models - Microsoft-backed OpenAI announced it is introducing OpenAI Data Partnership, where the generative AI company will work together with organizations to produce public and private datasets for training AI models. "Modern AI technology learns skills and aspects of our world - of people, our motivations, interactions, and the way we communicate - by making sense of the data on which it's trained," OpenAI said. "To ultimately make AGI that is safe and beneficial to all of humanity, we'd like AI models to deeply understand all subject matters, industries, cultures, and languages, which requires as broad a training dataset as possible. Including your content can make AI models more helpful to you by increasing their understanding of your domain. We're already working with many partners who are eager to represent data from their country or industry. For example, we recently partnered with the Icelandic Government and Mieind ehf to improve GPT-4's ability to speak Icelandic by integrating their curated datasets. We also partnered with non-profit organization Free Law Project, which aims to democratize access to legal understanding by including their large collection of legal documents in AI training. We know there may be many more who also want to contribute to the future of AI research while discovering the potential of their unique data. Data Partnerships are intended to enable more organizations to help steer the future of AI and benefit from models that are more useful to them, by including content they care about." Reference Link

14:00 EST Efficacy data from THIO 101 expected very soon, says MAIA CEO

14:00 EST Latest THIO data of 'highest quality,' MAIA CEO tells The Fly

13:01 EST Micromobility.com receives extension for continued listing on Nasdaq - Micromobility.com has received an extension from the Nasdaq Hearings Panel to continue its listing on the Nasdaq Capital Market. This decision is subject to the company meeting specific compliance criteria within designated timeframes. The Nasdaq Hearings Panel has stipulated that Micromobility.com Inc. must meet all the continued listing requirements, including the Bid Price and Market Value of Listed Securities requirements by the deadline of December 29, 2023.

12:44 EST Ionis reports 'positive' two-year results from Phase 2 OLE study of donidalorsen - Ionis Pharmaceuticals announced "positive" results from an ongoing Phase 2 open-label extension, or OLE, study evaluating the safety and efficacy of its investigational prophylactic medicine, donidalorsen, in patients with hereditary angioedema, or HAE. Over the two years, patients treated with donidalorsen via subcutaneous injection showed an overall sustained mean reduction in HAE attack rates of 96% from baseline, from 2.70 to 0.06 attacks per month, across all dosing groups. Furthermore, all patients treated with donidalorsen reported a clinically meaningful improvement in quality of life as measured by the Angioedema Quality of Life Questionnaire over two years. Treatment with donidalorsen was well tolerated in the studies, and there were no serious adverse events, the company reported.

12:02 EST Toyota Indiana starts production of Lexus TX SUV - Toyota Indiana has started production of the first-ever Lexus TX, an all-new, three-row luxury SUV. The 2024 TX is the first Lexus SUV to be assembled in the U.S., and the first Lexus for Toyota Indiana, Toyota said. In 2021, Toyota announced an $803M investment in Indiana to assemble two all-new SUV's, further cementing the automakers' commitment to U.S. manufacturing and to Toyota Indiana's workforce of more than 8,000 employees. "When Toyota Indiana was selected to assemble two brand-new vehicles, we were thrilled," said Leah Curry, Toyota Indiana president, "Being designated as a Lexus plant brings honor and prestige to the work we do every day and it's extremely gratifying to see our team recognized for their dedication and expertise."

12:00 EST ProAssurance falls -22.2% - ProAssurance is down -22.2%, or -$3.92 to $13.75.

12:00 EST Bloom Energy rises 15.9% - Bloom Energy is up 15.9%, or $1.59 to $11.62.

12:00 EST LiveRamp rises 20.4% - LiveRamp is up 20.4%, or $6.12 to $36.12.

11:33 EST Arogo Capital Acquisition terminates merger agreement with EON Reality - Arogo Capital Acquisition announced that its previously announced agreement and plan of merger with EON Reality has been terminated. As a result, Arogo will seek an alternative business combination.

11:05 EST Lyft announces launch of new partnership program with EVCS - EVCS, which identifies itself as "one of the largest electric vehicle fast-charging network operators on the West Coast," and Lyft announced the launch of a new partnership program via which EV drivers on Lyft can benefit from discounted charging on the EVCS network. "The program is available to all EV drivers on Lyft and encompasses all EVCS publicly accessible charging stations across California, Oregon, and Washington. Through this program, EV drivers on Lyft can enjoy exclusive access to discounts on charging in the form of pay-as-you-go or monthly subscription plans... All EV drivers on Lyft qualify for tiered discounts on charging, with Pro drivers receiving the highest discounts. Depending on their status and charging needs, an EV driver on Lyft will be able to save hundreds of dollars annually on their vehicle fueling costs," the companies stated.

11:03 EST Pharvaris presents clinical data on deucrictibant, real-world HAE treatment - Pharvaris announced the presentation of two ePosters at the American College of Allergy, Asthma & Immunology 2023 Annual Scientific Meeting, being held from November 9-13, 2023 in Anaheim, CA. Prof. Marc A. Riedl, M.D., M.S., will present a poster titled "Deucrictibant immediate-release capsule reduces time to end of progression of hereditary angioedema attacks' manifestations" on Friday, November 10, from 5:15-5:30 p.m. PST. In the phase 2 RAPIDe-1 trial, PHVS416 reduced time to the onset of symptom relief and to the resolution of HAE attacks, and substantially reduced use of rescue medication. End of progression of angioedema manifestations, which represents the first event documenting treatment response and the first evidence of attacks evolving towards relief and resolution, was assessed in a post-hoc analysis. All dose groups of PHVS416 achieved EoP at a median time of 25 or 26 minutes vs 20 hours for attacks treated with placebo. Dr. Joan Mendivil, M.D., will present a poster titled "Understanding the reasons not to treat all HAE attacks and satisfaction for on-demand treatment: physician- and patient-reported data" on Saturday, November 11, from 12:20-12:35 p.m. PST. Data detailed in the poster were drawn from the Adelphi HAE Wave II Disease Specific Program, a real-world, cross-sectional survey of people living with HAE and their treating physicians. People living with HAE reported a lower satisfaction with their current on-demand treatments than their treating physicians in terms of route of administration, discreteness to administer in public, time to resolve attacks, and ease of portability.

11:01 EST Teamsters to picked American Airlines, seeking improved compensation - On Thursday, November 9, passenger service workers at American Airlines who are members of the Communications Workers of America-International Brotherhood of Teamsters Association will hold an informational picket at Seattle-Tacoma International Airport as part of a national day of action at the second-largest passenger carrier in the world. "The workers have been in bargaining with the company for a year. They want the airline to improve wages, benefits, and job protections. Many of the workers have not received a raise in nearly four years, despite American Airlines reporting $13.5B in revenue last quarter."

10:44 EST Mr. Cooper says customer data compromised during cyberattack - Mr. Cooper has confirmed customer data was compromised during a recent cyberattack. In a notice on the company's website, the mortgage and loan giant said that, "On October 31, Mr. Cooper experienced a cybersecurity incident. Our team took immediate steps to lock down our systems, and we are working around the clock with cybersecurity experts to resolve this issue as soon as possible. As part of our ongoing investigation, we now believe that certain customer data was exposed. We are continuing to investigate precisely what information was exposed. In the coming weeks, we will mail notices to any affected customer and provide them with complimentary credit monitoring services." Reference Link

10:33 EST Bill.com Holdings trading resumes

10:29 EST BILL responds to market rumor, says 'not pursuing any such acquisition' - BILL responded to market rumors. The company said, "On November 8, 2023, a news agency issued an article about a rumored acquisition between BILL and another company. Although BILL's general policy is not to comment on market rumors or media speculation, BILL is not pursuing any such acquisition at this time."

10:24 EST eXp World Holdings reports putative class action complaint filed in Illinois - In a regulatory filing, eXp World Holdings disclosed that on November 2, a putative class action complaint under the caption "Batton et. al. v. Compass, Inc. et. al." was filed in the United States District Court for the Northern District of Illinois, Eastern Division, naming certain unaffiliated real estate brokerages, including the company, as defendants. "The Class Action alleges that defendants participated in a system that resulted in sellers of residential property paying inflated buyer broker commissions in violation of federal antitrust law. The plaintiffs seek a permanent injunction under federal antitrust laws enjoining the defendants from requiring home sellers to pay buyer-agent commissions without negotiations or from otherwise restricting competition among brokers and an award of declaratory relief and damages or restitution under the laws of various states on behalf of certain home buyers in those states, as well as attorneys' fees and costs of suit. Plaintiffs allege joint and several liability and seek treble or other multiple damages. The company believes that additional antitrust litigation may be possible. The company cannot provide any assurances that results of such litigation will not have a material adverse effect on its business, results of operations or financial condition," the filing stated.

10:16 EST Bristol Myers announces FDA acceptance of sBLA for Breyanzi - Bristol Myers Squibb announced that the U.S. Food and Drug Administration has accepted the supplemental Biologics License Application for Breyanzi to expand its current indication to include the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) who received a prior Bruton tyrosine kinase inhibitor and B-cell lymphoma 2 inhibitor. The FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act goal date of March 14, 2024. Priority Review designation underscores the high unmet need and the significant advancement Breyanzi may offer this patient population for which there is no standard of care and limited treatment options. The application was based on results from the primary analysis of the pivotal TRANSCEND CLL 004 study, a Phase 1/2, open-label, single-arm multicenter study, which were presented in an oral presentation during the 2023 American Society of Clinical Oncology Annual Meeting in June 2023. TRANSCEND CLL 004 is the first pivotal multicenter study to show clinical benefit with a CD19-directed CAR T cell therapy in patients with relapsed or refractory CLL after progression following treatment with a BTKi and BCL2i.

10:08 EST Enviva withdraws guidance, sees significantly lower sales price in Q4 - Enviva said this morning, "Due to the liquidity factors and comprehensive review outlined above, together with lower commercial activity in the third quarter of 2023 and the first part of the fourth quarter of 2023, the Company is withdrawing previous sales price per MT, net loss, adjusted EBITDA, and total capital expenditures guidance for 2023 and future years. Enviva generally experiences an uptick in biomass consumption in the fourth quarter of each year as winter heating demand coupled with seasonal impacts to the amount of solar and wind energy available to power grids drives higher commercial value and allows the Company to capitalize on increased wood pellet demand and higher spot prices. This dynamic, which was particularly pronounced in the fourth quarter of 2022, has not materialized to date in 2023. The Company is therefore expecting a significantly lower sales price per MT in the fourth quarter of 2023."

10:00 EST AMC Entertainment falls -14.2% - AMC Entertainment is down -14.2%, or -$1.43 to $8.66.

10:00 EST Carriage Services falls -19.3% - Carriage Services is down -19.3%, or -$4.39 to $18.43.

10:00 EST LiveRamp rises 19.0% - LiveRamp is up 19.0%, or $5.70 to $35.70.

09:56 EST Davis Commodities Ltd trading resumes

09:47 EST Bill falls -13.9% - Bill is down -13.9%, or -$8.64 to $53.55.

09:47 EST WideOpenWest falls -45.0% - WideOpenWest is down -45.0%, or -$3.33 to $4.07.

09:47 EST Braskem rises 16.5% - Braskem is up 16.5%, or $1.16 to $8.19.

09:46 EST Davis Commodities Ltd trading halted, volatility trading pause

09:42 EST WideOpenWest trading resumes

09:40 EST OneSpan trading resumes

09:37 EST WideOpenWest trading halted, volatility trading pause

09:32 EST Cardlytics trading halted, volatility trading pause

09:30 EST Tegna names Lauren Fisher chief legal officer, effective November 27 - TEGNA announced the appointment of Lauren Fisher as senior vice president and chief legal officer, effective November 27. Fisher will serve as a member of the company's leadership team, reporting directly to president and CEO Dave Lougee. As chief legal officer, Fisher will lead the company's legal department and oversee all legal functions across a broad range of disciplines including corporate, content creation and distribution, regulatory, ethics and compliance, and litigation and support TEGNA's long-term direction and growth. Fisher joins TEGNA from Vox Media where she was chief legal officer and corporate secretary.

09:24 EST Rumble to be exclusive RNC livestream provider for fourth GOP debate - Rumble will be the exclusive livestream provider for the fourth debate of the 2024 Republican Presidential Primaries. In partnership with NewsNation, The Megyn Kelly Show on SiriusXM, and the Washington Free Beacon, the debate will be held in Tuscaloosa, Alabama, on December 6, 2023. As the RNC's exclusive online home for the debates, Rumble will feature the event on the platform's homepage and make it available for viewers across the country on the RNC's Rumble channel.

09:18 EST Unique Fabricating trading halted, news dissemination

09:17 EST Applied DNA Sciences ships first saRNA IVT template generated by Linea platform - Applied DNA Sciences has manufactured and shipped its first research use only quantity of self-amplifying mRNA template generated by its Linea DNA platform to an unidentified preclinical therapeutic mRNA developer. saRNA is a promising new form of mRNA therapy engineered to possess a self-replicating capability. Unlike conventional non-amplifying mRNA, saRNA carries the machinery necessary for its replication, resulting in a higher therapeutic index at a lower dose. Due to these advantages, interest in saRNA is rapidly growing, as evidenced by 10 active saRNA vaccine clinical trials as of Jan. 20231 and numerous companies engaged in preclinical studies to use saRNA to treat indications ranging from cancer to protein replacement therapies. Like mRNA, saRNA is also produced from a DNA template. The manufacturing of saRNA, however, has proven to be challenging due to the large size and complexity of saRNA and its associated DNA IVT templates. The DNA templates for saRNA are often 3x-5x larger than the DNA templates for conventional non-amplifying mRNA. saRNA can also be challenging to produce efficiently in DNA plasmids, often leading to heterogeneous DNA sequences, low yields, and long manufacturing timelines.

09:16 EST Revolution Medicines completes acquisition of EQRx - Revolution Medicines (RVMD) announced it has closed its acquisition of EQRx (EQRX). Through the acquisition, Revolution Medicines expects to add approximately $1.1 billion in net cash proceeds to its balance sheet, after estimated post-closing EQRx wind-down and transition costs. Each share of common stock of EQRx issued has been converted into the right to receive 0.1112 shares of common stock of Revolution Medicines. Revolution Medicines expects to issue approximately 55 million shares of its common stock in connection with the merger. EQRx common stock has ceased trading on the Nasdaq Global Market and all EQRx programs are being wound down. "Revolution Medicines has reached an important milestone with the completion of this transaction that brings a significant additional quantum of capital to support our rapidly advancing clinical programs. On the foundation of exciting recent scientific disclosures, we will be able to make significant investments on behalf of the parallel clinical development strategy for our compelling RASMULTI Inhibitor, RMC-6236, and mutant-selective RAS Inhibitors, RMC-6291, and RMC-9805, which we believe have the potential to change the standard of care for patients with RAS-addicted cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "We are also delighted to welcome Dr. Sandra Horning, a seasoned oncologist and late-stage clinical development leader, to the Revolution Medicines board of directors. We remain deeply committed to advancing our rich pipeline of promising oncology assets to address unmet patient needs, and I am extremely grateful to the employees and shareholders of Revolution Medicines and EQRx who have supported us to a successful transaction."

09:12 EST Bitfury announces sale of 10M shares of Cipher Mining, lock-up agreement - Bitfury Group has sold 10,000,000 shares of the common stock of Cipher Mining at a price of $2.95 per share in a privately negotiated transaction. Cipher, a U.S.-based Bitcoin mining company, operated as a subsidiary of Bitfury prior to August 27, 2021. The common shares were offered pursuant to Cipher's Form S-3 shelf registration statement and represent 4.95% of Bitfury's current ownership of Cipher's common shares. Bitfury will receive all net proceeds from the sale. Upon completion of the transaction, Bitfury will hold 191,931,387 shares, or approximately 75.37% of the common stock of Cipher. Bitfury has entered into a 60-day lock-up agreement with respect to its remaining holdings of Cipher common stock, pursuant to which the Company may not sell or transfer any of the common stock before January 15, 2024.

09:10 EST GitLab continues AI momentum with AI-powered DevSecOps workflows - GitLab announced updates to GitLab Duo, the company's suite of AI capabilities, including the beta of GitLab Duo Chat available in the GitLab 16.6 November product release, and the general availability of GitLab Duo Code Suggestions in the GitLab 16.7 December product release. GitLab Duo Chat, a powerful natural-language AI assistant, provides users with real-time guidance, insights, and suggestions to help analyze code, assist with planning, understand and fix security issues, troubleshoot CI/CD pipeline failures, assist with merge requests, and more. Duo Chat beta joins Code Suggestions as one of the two primary interfaces into GitLab's AI-powered suite within its DevSecOps platform.

09:09 EST Artelo Biosciences announces publication of peer-reviewed research on ART27.13 - Artelo Biosciences announced new research published in the peer-reviewed journal Pharmaceuticals. The research article, titled "Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration is Prevented via Cannabinoid Receptor 2 Agonism in Vitro," highlights the promising protective properties of the Company's clinical asset, ART27.13, in helping prevent muscle degeneration caused by cancer. Artelo is currently evaluating ART27.13, a dual CB1/CB2 receptor agonist, in the Cancer Appetite Recovery Study Phase 2a clinical trial to determine its effect on lean body mass, weight gain, activity levels, and improvement of anorexia in cancer patients. The purpose of this new research was to establish whether ART27.13 may additionally impact muscle degradation, a common debilitating effect of cancer and its treatment. Not only did the research show that ART27.13 protects against muscle wasting in the in vitro model, but also shows that the activity was mediated by the CB2 receptor.

09:07 EST Micron announces 32Gb monolithic die-based 128GB DDR5 RDIMM memory - Micron Technology announced its 32Gb monolithic die-based 128GB DDR5 RDIMM memory featuring best-in-class performance of up to 8000 MT/s1 to support data center workloads today and into the future. These high-capacity, high-speed memory modules are engineered to meet the performance and data-handling needs of a wide range of mission-critical applications in data center and cloud environments, including artificial intelligence, in-memory databases and efficient processing for multithreaded, multicore count general compute workloads. Powered by Micron's industry-leading 1beta technology, the 32Gb DDR5 DRAM die-based 128GB DDR5 RDIMM memory delivers the following enhancements over competitive 3DS through-silicon via products: more than 45% improved bit density; up to 24% improved energy efficiency; up to 16% lower latency; up to a 28% improvement in AI training performance.

09:06 EST Comtech receives $20M order from Spectra Group - Comtech announced the receipt of a $20M order from the company's UK-based partners, Spectra Group. The order will allow Spectra Group, the appointed regional distributor of Comtech's Compact Over-the-Horizon Transportable Terminal, or COMET, to service multiple orders already received, and several expected follow-on orders from undisclosed customers in the NATO and European regions.

09:04 EST GSE Systems selected as engineering services provider by nuclear power supplier - GSE Solutions announced that a Southeast Texas power supplier has selected GSE to be a preferred engineering services provider for their two pressurized water reactor plants. GSE is one of three preferred engineering services providers listed by the utility for work to be done at these plants in 2024.

09:03 EST Adamas One forms new wholly owned subsidiary, Adamas Technologies - Adamas One announced the formation of its new wholly owned subsidiary, Adamas Technologies. Adamas Technologies will be responsible for research & development, partnerships, and deployment of Lab-Grown Diamond-based solutions for the technology industry. Lab-Grown Diamonds' thermal conductivity and durability make them ideal for use in semiconductor devices in the industrial and technology sectors. Adamas' patented technology provides a significant opportunity to address increasing demand from the semiconductor sector.

09:02 EST Precision Optics receves production order for robotic laparoscopy system - Precision Optics received an $890K initial production order for a complex imaging sub-assembly that will be used in the customer's new robotic laparoscopy system. The imaging subassembly incorporates optical, electronic and mechanical systems designed by Precision Optics. This initial production order is expected to be delivered between January and October 2024 with follow on production orders expected.

08:57 EST Ondas enters strategic partnership with Maghrebnet - Ondas Holdings signed a Memorandum of Understanding with Maghrebnet, a Moroccan vendor specialized in information technologies, security, networks, telecommunications, electricity, and renewable energies. Through this partnership, Ondas expands into the Moroccan and broader North African market, offering advanced drone infrastructure for cities, industrial, and strategic facilities. As part of the MOU, Ondas and Maghrebnet have agreed to jointly explore a multi-faceted business partnership. Maghrebnet will introduce Ondas' systems to potential customers in the region and will handle the manufacturing and sales of Onas' automated Optimus Drone-In a-Box systems in Morocco and Senegal. Based on future growth, the companies will work towards achieving cost-effective manufacturing of docking stations and establishing a joint Research and Development Center in Morocco. This center aims to enhance existing products, develop new features, and explore innovative solutions, actively participate in local bid competitions for projects, and serve as a hub for talent acquisition, development, and management within the local market. The parties will jointly recruit, train, and manage a skilled workforce to support the operations of the center and contribute to the success of various initiatives.

08:56 EST Jaguar Health's Napo to present results of quality of life survey - Napo Pharmaceuticals announced that the results of "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer," an online, anonymous Napo-supported survey initiative of Advocates for Collaborative Education to shed light on the diverse and profound challenges faced by individuals living with a diagnosis or a history of cancer, have been accepted for presentation at the December 2023 San Antonio Breast Cancer Symposium. The survey received more than 500 responses and will offer a unique perspective on the experiences and priorities of those affected by cancer. Only the breast cancer related responses will be presented at SABCS, with the remainder of the results to be shared at subsequent oncology symposia and conferences. Advocates for Collaborative Education co-created the survey with patients and survivors to design relevant questions whose answers may help the cancer ecosystem better understand the far-reaching impacts of a cancer diagnosis and treatment on quality of life. The results of this study are poised to transform the way we approach cancer care and support, potentially addressing not only the clinical aspects but also the physical, emotional, social, financial, and psychological impacts on those affected by this relentless disease.

08:54 EST Agape ATP to finance construction of 50 EV charging stations by Volt - AGAPE ATP Corporation intends to finance the construction of 50 electric vehicle charging stations by Volt Industries Sdn. Bhd. in Pahang as part of the Company's strategy to develop and offer sustainable energy solutions. On 4th November, 2023, ATPC signed a Memorandum of Agreement with Volt Industries, pursuant to which the Company intends to acquire a 51% stake in Volt Industries, a developer of EV charging stations based in Pahang, and the Company also intends to finance the construction of 50 EV charging stations by Volt Industries. ATPC, which was recently listed on Nasdaq, specializes in sustainable global 'wellness' ecosystem and the development and production of advanced technology solutions for the energy sector. Under the MoA, ATPC will explore the project's financial viability by securing primary funding as well as seeking additional capital from other avenues. Volt Industries will initiate the project's groundwork, including acquiring all necessary permits and licenses as well as ensure full compliance with local regulations together with construction work.

08:52 EST NeoVolta adds $520,000 purchase order for solar battery storage in New Mexico - NeoVolta announced that it has expanded its presence as a leading home solar power storage in the state of New Mexico, with a high six-figure deal that places NeoVolta NV14 batteries in new home construction projects across the state. "This order is the first of what we expect to be many follow-on orders over the coming years and indicates strong demand for NeoVolta's energy storage products, with New Mexico being the latest state to embrace our solar batteries," said Brent Willson, CEO of NeoVolta. "Our all-in-one NV14 storage system provides safe, reliable backup power during an outage when you need it most. And during normal conditions, it's the perfect solution for escaping skyrocketing utility costs. A key decision factor in selecting NeoVolta is our UL 9540A battery certification, as well as the ability to couple with DC solar, meaning the NV14 battery is a No Fire solution that's also more efficient than the competition." NeoVolta is proud to add New Mexico to its growing list of states where NeoVolta systems are installed, including California, Arizona, Nevada, Utah, Oklahoma, Georgia, Florida, Texas, Colorado, Tennessee, Alabama, Georgia, Kentucky, Illinois, Wyoming, and the territory of Puerto Rico.

08:51 EST Calian Group to acquire Decisive Group for up to C$74.7M - Calian Group is entering into a definitive purchase agreement to acquire 100% of the shares of Ottawa-based Decisive Group Inc. for up to CAD$74.7M.This includes the amount to be paid in cash at closing of CAD$50M. Decisive Group is a leader in the IT infrastructure and cyber security services business in the Ontario region with a long legacy of working with customers to evolve their IT environment. It designs, builds, and maintains enterprise IT infrastructure and hybrid cloud, as well as manages and protects data. Its customer base primarily includes Canadian government departments and agencies, as well as some well-established commercial and enterprise clients. Established in 2001, Decisive Technologies was founded as a professional services company in Canada's National Capital Region and began offering data centre solutions in 2010. It expanded its offerings in 2013 with the addition of BriteSky Technologies, which originally focused on cloud storage, and in 2021, the companies amalgamated their products and services under the Decisive Group banner. The definitive purchase agreement is effective immediately. Calian anticipates the transaction to close by the end of calendar 2023, pending regulatory approvals. Financial metrics are reported in Canadian dollars and in accordance with IFRS reporting standards.

08:49 EST Milestone starts sales of ComuFlo disposables within Island Ambulatory Center - Milestone Scientific announced that it has commenced sales of CompuFlo Epidural disposables into Island Ambulatory Surgery Center, a multi-specialty ambulatory surgery center based in Brooklyn, New York with a focus on pain management, orthopedics and spine care, urology, podiatry and plastic surgery. Island Ambulatory Surgery Center is affiliated with Mount Sinai Health System, MSHS, which operates 19 hospitals across New York. Adoption of the technology by this center follows a successful evaluation process by its founder and medical director, Dr. Leon Reyfman, MD, MBA, an interventional pain medicine physician, who is board-certified by the American Board of Anesthesiology in both anesthesiology and pain medicine. Arjan Haverhals, CEO and president of Milestone Scientific, stated, "We are proud to announce the adoption of our technology by Island Ambulatory Surgery Center, following a successful evaluation period. Moreover, this marks an important milestone as it represents the first commercial adoption of the CompuFlo(R) Epidural System within an ambulatory surgery center."

08:46 EST Elutia completes divestiture of Orthobiologics business unit - Elutia announced it completed the divestiture of its Orthobiologics business unit to Berkeley Biologics, a wholly owned subsidiary of GNI Group Ltd. The transaction enables Elutia to strategically focus on its proprietary drug-eluting biomatrix platform and provides the Company with cash proceeds of up to $35 million, comprised of upfront payments no later than November 17, 2023 of $15 million plus potential earnout payments of up to $20 million over a five-year period. Combined proceeds with the previously announced September 2023 private placement potentially top $60 million. "With the closing of this transaction, Elutia is now fully focused on our high-growth biomatrix product platforms, including our near-term blockbuster opportunity with CanGarooRM," said Dr. Randy Mills, President and Chief Executive Officer of Elutia. "The proceeds from this transaction, coupled with the September financing, should have us well-capitalized to advance our proprietary drug-eluting biomatrix platform. And all of this is made possible by the outstanding work of our team, which continues to execute the Elutia plan with relentless drive and focus."

08:46 EST Bitcoin Depot announces distribution partnership with CORD Financial Services - Bitcoin Depot announced its partnership with CORD Financial Services, CORD, a leading provider of innovative ATM solutions, to distribute Bitcoin Depot kiosks across the U.S. CORD and Bitcoin Depot will secure Bitcoin ATM placements within CORD's established base of customers and to customers new to CORD. In addition to now offering Bitcoin ATM services, CORD is a leader in the ATM Services Business, offering full-service ATM placements, cash management, transaction processing, merchant services, ATM equipment, sales, and 24/7 customer and technical support. "This partnership will allow Bitcoin Depot to expand our retail locations while leveraging CORD's expertise and customer relationships in the ATM industry," said Bitcoin Depot CEO Brandon Mintz. "CORD has an impressive history of reliable ATM services and a demonstrated mastery of the conventional ATM space. We look forward to leveraging their relationship network and brand awareness to drive additional placement opportunities for our business."

08:44 EST Mainz Biomed partners with Liquid Biosciences for colorectal screening test - Mainz Biomed announced a strategic partnership with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform to serve the biopharma and diagnostics industries along with academic institutions. The collaboration builds upon Mainz Biomed's initial utilization of EMERGE to analyze the Company's ColoFuture study, which recently reported groundbreaking results including sensitivity for colorectal cancer of 94% with a specificity of 97% and a sensitivity for advanced adenoma of 80%. ColoFuture is an international multi-center clinical trial which assessed the potential to integrate a portfolio of novel gene expression biomarkers into ColoAlert, Mainz Biomed's highly efficacious, and easy-to-use screening test for colorectal cancer being commercialized across Europe and in select international territories. This proprietary family of mRNA biomarkers represents a potentially game-changing innovation in CRC screening as the portfolio has previously demonstrated the ability to detect CRC lesions, including advanced adenomas, a type of pre-cancerous polyp often attributed to this deadly disease. Under the terms of the partnership, the utility of EMERGE in Mainz Biomed's product development pipeline will be extended to include analysis of its eAArly DETECT study and the forthcoming U.S. pivotal FDA PMA trial which, if successful, will enable Mainz Biomed to further advance its current test's capabilities and commercialize a next-generation, gold standard, self-administered CRC screening tool. The eAArly DETECT clinical trial, a multi-center feasibility study is enrolling 265 subjects across 22 sites and remains on track to report results in Q4 2023. The goal at completion will result in a single fixed machine learning/AI-based algorithm, developed utilizing the evolutionary EMERGE platform, integrated into the next-generation product's test report.

08:42 EST Recursion enters data collection deal with Tempus, updates focus of Bayer collab - Recursion announced two significant updates with their collaborators NVIDIA and Bayer, and a new collaboration with Tempus Labs as it creates infrastructure and expands its ambitions and scope in the precision oncology space. Recursion has come to an agreement with Tempus for preferred access to one of the world's largest proprietary, de-identified, patient-centric oncology datasets, spanning DNA, RNA, health records and more to support the discovery of potential biomarker-enriched therapeutics at scale through the training of causal AI models. By combining the forward genetics approach of Tempus with the reverse genetics approach at Recursion, the company believes it has an opportunity to improve the speed, precision and scale of therapeutic development in oncology. As part of the agreement, Recursion will pay Tempus up to $160M in cash or equity over the next five years in exchange for continued and updated data access and use rights for therapeutic development purposes. In aggregate, Recursion will now have access to approximately 50 petabytes of proprietary data across biology and chemistry as well as real-world, patient-centric data that is relatable and fit for the purpose of training large-scale AI/ML models, which it plans to use to drive novel therapeutic hypotheses, biomarker strategies, and patient cohort selection. To accelerate the impact of the proprietary data Recursion has accumulated, the company has committed to substantially expanding BioHive-1, its on-premise NVIDIA DGX SuperPOD-based supercomputer, adding over 500 NVIDIA H100 Tensor Core GPUs to the more than 300 NVIDIA A100 Tensor Core GPUs already in place to increase its computational capacity 4X. This greatly expanded compute power will support the company's pipeline, partnerships, and the construction of one of the largest foundation models of its kind across multiple modalities of biology and chemistry. Based on the June 2023 TOP500 list, Recursion projects that upon completion and benchmarking, BioHive-1 will likely be in the top 50 most powerful supercomputers in the world across any industry and would be the most powerful supercomputer owned and operated by any biopharma company. The company anticipates the enhancement of BioHive-1 to be operational in the first half of 2024. Recursion announced an updated collaboration with its established partner, Bayer, for a select set of precision oncology programs. This decision allows Bayer to leverage Recursion's state-of-the-art capabilities to identify novel targets and chemistry applicable to oncology indications. Under the terms of the agreement, the companies may initiate up to seven oncology programs and Recursion is eligible to receive potential, success-based, future payments of up to $1.5 billion plus royalties on net sales.

08:40 EST Genasys enters partnership with Ladris Technologies - Genasys announced its partnership with Ladris Technologies, Inc., an artificial intelligence software provider, to deliver comprehensive disaster evacuation modeling solutions across North America and Europe. Ladris software allows emergency managers, fire departments, law enforcement agencies, and other public sector officials to simulate detailed population responses for all-risk emergencies, including evacuation times and traffic conditions across any number of what-if scenarios. Through this combined solution, emergency managers, law and fire officials can use reliable, local data and evacuation zones for planning and operations, increasing pre-planning capabilities and situational awareness. This is particularly valuable for designing and executing progressive evacuation strategies and making key decisions for traffic control, congestion management and infrastructure optimization. Traditionally, it took years and significant expense to use data to manage and plan evacuations. First responders were often using historic, static data when it came to answering the question of how long it might take to evacuate a region. Now, emergency management personnel have advanced models to forecast evacuation times and optimize based on critical intelligence. This additional level of intelligence is key in fast-moving scenarios such as wildfires, where time is of the essence.

08:38 EST Dentsply Sirona board authorizes additional $1B share repurchase program - The Company is announcing that its Board of Directors has authorized an additional $1 billion share repurchase program.

08:35 EST Stagwell partners with Google Cloud for generative AI solutions - Stagwell (STGW) announced a unique partnership with Google (GOOG) Cloud and SADA, a Google Cloud Premier Partner, to develop generative AI marketing solutions that support Stagwell agencies, client partners, and product development within the Stagwell Marketing Cloud, or SMC. Through this collaboration, SMC will build AI-based tools for marketers and receive development support from Google Cloud as a strategic cloud and AI provider. Additionally, SMC plans on releasing its solutions on Google Cloud Marketplace in the future, scaling access to Stagwell's marketing-focused AI-enabled product suite.

08:32 EST Third Harmonic Bio expects cash to fund requirement through at least 2025 - Cash and cash equivalents totaled $273.9 million as of September 30, 2023. Based on the company's current operating plan, Third Harmonic Bio believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through at least 2025.

08:29 EST Collegium Pharmaceutical announces $25M accelerated share repurchase program - Collegium Pharmaceutical announced that it has entered into an Accelerated Share Repurchase, ASR, agreement with Jefferies to repurchase $25M of the Company's common stock. Collegium will execute the ASR as part of the $100 million share repurchase program authorized by its Board of Directors in January 2023. Upon completion of this ASR, Collegium will have $25 million remaining under the program. "Our record financial performance in 2023 year-to-date puts Collegium on track to deliver a banner year. Our financial strength, underscored by robust cash generation, enables us to execute on our capital deployment strategy," said Joe Ciaffoni, President and Chief Executive Officer of Collegium. "We are committed to opportunistically returning value to our shareholders through our share repurchase program. Since 2021, we have returned $112 million of capital to our shareholders through share repurchases. This additional $25 million ASR program is a productive use of our capital with the potential to generate high returns for our shareholders." Under terms of the agreement, Collegium will pay $25M to Jefferies LLC and will receive an initial delivery of approximately 865,426 shares, based on the $23.11 closing stock price of Collegium's common stock on November 8, 2023, representing approximately 80% of the total shares the Company expects to repurchase under the ASR agreement. The final number of shares repurchased will be based on the volume-weighted average prices of Collegium's common stock during the term of the ASR and subject to adjustments related to the terms and conditions of the ASR agreement. The final settlement of the ASR is expected to be completed in the fourth quarter of 2023.

08:28 EST HEALWELL AI makes investment, launches alliance with doctorly - HEALWELL AI has made a strategic investment in doctorly GmbH, a medical practice management software provider based in Germany. This partnership marks HEALWELL's entrance into the European healthcare technology landscape. doctorly is a digital health tech startup that has built a cloud-based, fully regulated practice management software to redefine how medical practices work. HEALWELL invested as part of a syndicate of venture investors which included Simon Capital, Geschwister and Oetker Beteiligungen. This financing round is in addition to the March 2023 investment in doctorly by HEALWELL's largest shareholder, WELL Health Technologies Corp and a syndicate of investors, including Horizons Ventures, The Delta Force AG, Speedinvest, UNIQA Ventures, Calm Storm and Seedcamp. HEALWELL and doctorly have also entered into a strategic alliance agreement, which provides HEALWELL with access to doctorly's rapidly expanding network of healthcare providers. This strategic alliance is expected to enhance HEALWELL's ability to deploy cutting-edge technology for the early detection and risk stratification of patients for various diseases, which would ultimately lead to better patient outcomes for physicians using doctorly's medical practice management software.

08:26 EST Daxor awarded new patent for remote monitoring of blood volume - Daxor announces that Daxor was recently granted a patent for a system to provide remote blood volume monitoring after initial testing with Daxor BVA-100 diagnostic. This U.S. patent number adds to our existing portfolio that includes more than a dozen issued and pending-review patents. The recently issued patent provides remote blood volume monitoring through various methods including wearable devices such as smartwatches for a wide variety of medical conditions for which volume assessment is recommended. This proprietary technology will help ensure ongoing care is optimized based on the patient's evolving blood volume status. "Daxor has a robust research and development program focused on innovation and next-generation technologies, including approaches to blood volume optimization that rely on leveraging smart algorithms, computer-assisted clinical decision support, and novel hardware. These efforts are supported by funding we have received from the National Institute of Health and United States Department of Defense and are part of our strategy of adding significant intellectual property assets to the company to fuel future product development," said Michael Feldschuh, Chief Executive Officer of Daxor.

08:24 EST Establishment Labs gets NMPA approval in China for Motiva Implants - Establishment Labs Holdings announced it has received National Medical Products Administration NMPA approval in China for Motiva Implants. "Our approval in China marks Establishment Labs' entry into the second largest global and most dynamic market for breast aesthetics in the world," said Juan Jose Chacon-Quiros, Chief Executive Officer. "This is the first breast implant technology approved in China in more than a decade. Many Chinese plastic surgeons are familiar with Motiva Implants from other Asian countries where we have leading market shares, and we expect they will adopt our technology as their first choice." "We transformed the breast aesthetics market in South Korea with Motiva, and we are excited to replicate that success in China," added John Lim, Founder and CEO of Motiva China Ltd., Establishment Labs exclusive distribution partner in the market. "Three years after launching in Korea in 2016, we became the market leader. Today, Motiva is far and away the most chosen and most recognized brand in Korea. Most importantly, we changed the perception of our industry. Chinese plastic surgeons and consumers are highly attuned to the latest innovations in science and technology, and, just like the Koreans, we expect they will recognize Motiva as truly innovative and differentiated."

08:22 EST Tegna enters into $325M accelerated share repurchase pact - Tegna announced that it has entered into an accelerated share repurchase agreement or ASR with JPMorgan Chase Bank, National Association...Under the terms of the ASR, TEGNA will repurchase $325 M in TEGNA common shares from JPMorgan, with an initial delivery of approximately 17.3M shares on November 13. The final number of shares to be repurchased will be based on the average daily volume-weighted average price of TEGNA shares during the term of the ASR, less a discount and subject to customary adjustments pursuant to the terms of the ASR. The final settlement of the ASR is expected to be completed by the end of the first quarter of 2024, subject to acceleration at JPMorgan's discretion. TEGNA completed its initial $300 M ASR program on August 31 earlier than anticipated. Following the completion of the initial ASR and before entering TEGNA's third quarter blackout period on September 16, the Company opportunistically repurchased an incremental $28 Mof shares taking advantage of attractive market pricing. The repurchases were made under TEGNA's existing share repurchase program approved by the Board of Directors in December of 2020. The initial $300M ASR program reduced the Company's outstanding shares by approximately 18 million, including final settlement of approximately 3M shares.

08:20 EST Infosys, Better Home & Finance announce collaboration - Infosys (INFY) announced a collaboration with Better Home & Finance Holding Company (BETR) to launch Mortgage as a Service, an integrated end-to-end digital mortgage white-labelled platform. By adopting Infosys-Better white-labelled MaaS, organizations can revolutionize their mortgage operations. Better's proprietary digital technology is an end-to-end platform including point of sale, pricing, underwriting, loan origination, closing, funding and investor sale - built to be cloud-native. Better has already funded over $100B in fully digital loans for the industry, and their status as an industry leader is reflected in their client Ally's ranking as the #1 Digital Mortgage Platform by J.D. Power. Infosys is one of the world's largest digital service providers to mortgage firms helping them to strengthen their technology and operations. With its digital-first, cloud-first and AI-first approach, Infosys is best equipped to help its clients to reap the advantages of Mortgage as a Service faster.

08:18 EST Core & Main signs agreement to acquire Granite Water Works, no terms - Core & Main has entered into a definitive agreement to acquire substantially all of the assets of Granite Water Works Inc., a provider of water, wastewater and storm drainage products in Minnesota. "The strong local relationships and commitment to dependable service that Granite Water Works will bring to Core & Main will greatly amplify our capabilities and presence in central Minnesota," said Steve LeClair, chief executive officer of Core & Main. Granite Water Works is a leading distributor of high-quality waterworks and subsurface drainage supplies for contractors and municipalities in central Minnesota. Since 1990, their experienced team has consistently delivered high-quality products and personalized service to their customers from their Waite Park, Minnesota, location. "Granite Water Works has firmly established itself as a trusted partner to contractors and municipalities in its community," said Jack Schaller, president of Core & Main. "The depth of local market knowledge its team brings makes it a terrific addition to our existing business, and we look forward to welcoming the team into the Core & Main family."

08:09 EST Phathom Pharmaceuticals expects cash to fund operations through end of 2025 - Based on its current operating plan, including expected product revenues, the funds available under its existing term loan with Hercules and cash to be paid under our royalty interest financing agreement based on the recent approval of VOQUEZNA for Erosive GERD, Phathom believes it will have sufficient capital to fund operations through the end of 2025.

08:06 EST Byrna Technologies secures order from State of Hawaii Sherriff's Division - Byrna Technologies announced it has supplied the State of Hawaii Sherriff's Division with 100 Byrna SD launchers, along with ammunition and accessories. Byrna began engaging with the State of Hawaii Sherriff's Division in May of 2022. The agency diligently evaluated various less-lethal platforms before ultimately selecting Byrna as their preferred choice. The introduction of Byrna devices into Hawaii will commence on the island of Oahu immediately, with plans for expansion to other islands within the state in the near future.

07:56 EST ARway.ai expands SaaS augmented reality experience platform - ARway.ai announces ten new developer SaaS subscription deals starting at $249/month from countries around the globe, targeted at various industries and use-cases leveraging ARway's groundbreaking augmented reality technology. ARway.ai currently has over 3,000 user accounts signed up for its platform which represent additional future potential revenue.

07:55 EST Laser Photonics receives order from fabrication company - Laser Photonics received an order for its CleanTech LPC-1000-CTHS laser cleaning system. Taller de Soldadura Rodriguez, a fabrication and vehicle modification company based in Costa Rica, was looking for a cost-effective and time-efficient method of cleaning parts on the vehicles they work on. For this reason, they purchased a laser cleaning system from Laser Photonics that can effectively remove corrosion, contaminants, and coatings.

07:51 EST Studio City Finance announces tender offer for up to $75M of senior notes - Studio City Finance has initiated a cash tender offer for up to an aggregate principal amount of $75 million of its outstanding 6.000% senior notes due 2025. The Tender Offer is being made upon and is subject to the terms and conditions set out in the Offer to Purchase, dated November 9, 2023. The Tender Offer will expire at 5:00 p.m., New York City time, on December 8, 2023, unless extended or terminated by Studio City Finance. Tenders of the Notes may be withdrawn at any time at or prior to 5:00 p.m., New York City time, on November 22, 2023, but may not be withdrawn thereafter except in certain limited circumstances where additional withdrawal rights are required by law. The consideration for each US$1,000 principal amount of Notes validly tendered on or prior to 5:00 p.m., New York City time, on November 22, 2023, and accepted for purchase will be US$975, which includes an early tender premium. The consideration for each US$1,000 principal amount of Notes validly tendered after the Early Tender Date and on or prior to the Expiration Time and accepted for purchase will be US$945. Notes will be accepted only in minimum denominations of US$200,000 and integral multiples of US$1,000 in excess thereof. The Notes may be subject to proration if the aggregate principal amount of the Notes validly tendered would cause the Maximum Tender Amount to be exceeded.

07:49 EST Eagle Pharmaceuticals is delaying the release of its Q3 results - Eagle Pharmaceuticals announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023, and expects to file its Form 10-Q by November 14, 2023, prior to the expiration of the extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934. The Company requires more time to review potential adjustments relating to the reporting of sales of PEMFEXY prior to filing its Form 10-Q. In addition, the Company expects to revise its previously disclosed 2023 full year guidance downward. "We remain confident in the strength of our business and our outlook for 2024, and we look forward to reporting on our commercial portfolio, progress on our pipeline and other initiatives," stated Scott Tarriff, President and CEO of Eagle.

07:46 EST Boralex to continue to work on initiatives under 2025 Strategic Plan - Boralex's 2025 Strategic Plan is built around the same four strategic directions as the plan launched in 2019 - growth, diversification, customers and optimization - and six corporate targets. The details of the plan, which also sets out Boralex's corporate social responsibility strategy, are found in the Company's annual report. Highlights of the main achievements for the quarter ended September 30, 2023, in relation to the 2025 Strategic Plan can be found in the 2023 Interim Report 3, available in the Investors section of the Boralex website. In the coming quarters, Boralex will continue to work on its various initiatives under the strategic plan, including project development, analysis of acquisition targets and optimization of power sales and operating costs. Finally, to pursue its organic growth, the Company has a pipeline of projects at various stages of development defined on the basis of clearly identified criteria, totalling 6.4 GW of wind, solar and energy storage projects.

07:45 EST Calumet Specialty Products transitioning to new Delaware corporation - Calumet Specialty Products Partners announced the execution of an agreement to effectuate a corporate transition of Calumet Specialty Products Partners to a new Delaware corporation. The Board of Directors of the General Partner has unanimously approved the terms of the agreement. Each common unit representing a limited partnership interest in the Partnership will be converted into the right to receive one share of New Calumet's common stock. All incentive distribution rights in the Partnership and the 2.0% General Partner interest in the Partnership will be converted into the right to receive 5.5 million shares of Common Stock and 2.0 million warrants with a three-year term and an exercise price of $20.00 per share, which shares and warrants will be issued to the owners of the General Partner. New Calumet will be governed by a board of directors of nine directors. Completion of the Corporate Transition is subject to customary conditions including the approval by the Partnership's unitholders at a special meeting and the customary closing conditions of the associated agreements having been satisfied or waived. The associated merger is intended to be tax-free to unitholders subject to potential recapture for some unitholders as a result of the change in tax status from a partnership to a C-Corporation. The Corporate Transition is expected to close within nine months.

07:44 EST Phio announces first U.S. patient enrolled in Phase 1b trial with PH-762 - Phio Pharmaceuticals announced that the first patient has been dosed in the Phase 1b clinical trial of PH-762, an INTASYL compound that reduces the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. This clinical trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. "The initiation of enrollment in this trial represents a milestone as we develop PH-762 for the treatment of squamous cell and other skin cancers," said Phio's President and CEO Robert Bitterman. "We are optimistic that this novel, alternative immuno-oncology therapy may offer patients and their care providers, enhanced therapeutic outcomes while minimizing invasive intervention."

07:41 EST ZyVersa Therapeutics announces article on NLRP3 in an IBD animal model - ZyVersa Therapeutics announces publication of an article in the peer-reviewed Biomedical Journal demonstrating that inhibiting NLRP3 inflammasomes in an IBD animal model attenuates intestinal inflammation and tissue damage, leading to significant improvements in IBD symptoms, and restoration of normal intestinal microbial flora. In the paper titled, "Inhibition of NLRP3 attenuates sodium dextran sulfate-induced inflammatory bowel disease through gut microbiota regulation," the authors evaluated human colon biopsy samples from patients with IBD and healthy controls, and conducted a study in an IBD mouse model. Following are key findings reported in the paper: NLRP3 and IL-1beta expression is increased in the colon of IBD patients. NLRP3 inhibition in the IBD animal model: Inhibited NLRP3 inflammasome signaling in the colon, resulting in significantly reduced levels of the pro-inflammatory cytokines IL-1b, IL-6, and TNF-alpha. Alleviated severe diarrhea and significantly improved IBD symptoms, based on the disease activity index score. Attenuated histopathological changes indicative of tissue damage. Restored gut microbiota to normal. "Restoration of quality of life is the ultimate long-term goal in IBD management. Although disease remission can often be achieved with current therapies, bothersome symptoms can still prevail," stated Stephen C. Glover, ZyVersa's Co-founder, Chairman, CEO and President. "The research published in the Biomedical Journal provides support for inflammasome inhibition as a promising treatment option for IBD. ZyVersa is developing Inflammasome ASC inhibitor IC 100. Unlike NLRP3 inhibitors, designed to inhibit formation of one inflammasome to block initiation of the inflammatory cascade, IC 100 was designed to inhibit multiple types of inflammasomes and their associated ASC specks to uniquely block both initiation and perpetuation of damaging inflammation, which we believe is necessary to control chronic inflammation."

07:37 EST Scorpio Tankers increases quarterly dividend to 35c per share - On November 9, 2023, the Board of Directors declared a quarterly cash dividend of $0.35 per common share, with a payment date of December 15, 2023 to all shareholders of record as of November 30, 2023. As of November 9, 2023, there were 53,107,765 common shares of the Company outstanding.

07:35 EST Ares Capital appoints Treasurer Scott Lem as CFO - Ares Capital C announced that Ares Capital's Chief Accounting Officer, Vice President and Treasurer, Scott Lem, has been appointed as its new Chief Financial Officer, effective February 15 Mr. Lem succeeds Penni Roll, who plans to step down as Ares Capital's Chief Financial Officer, effective the same date. Ms. Roll, who also serves as the Chief Financial Officer of Ares Management Corporation's Credit Group, will remain an officer of Ares Capital and at Ares in a senior leadership capacity.

07:33 EST AstraZeneca: Imfinzi+bevacizumab met primary endpoint for PFS in liver cancer - First global Phase III trial to show improved clinical outcome for systemic therapy in combination with transarterial chemoembolization TACE in this setting Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca's IMFINZI or durvalumab in combination with transarterial chemoembolization TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival PFS versus TACE alone in patients with hepatocellular carcinoma HCC eligible for embolization. The trial continues to follow the secondary endpoint of overall survival OS . Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "These positive results for IMFINZI-based treatment in EMERALD-1 may bring the potential of immunotherapy to patients with earlier stages of liver cancer. We look forward to discussing these data with regulatory authorities and seeing the survival data mature over time, which will be important as we aim to bring this novel treatment option to patients." The safety profiles for IMFINZI and TACE plus bevacizumab were consistent with the known profile of each medicine, and there were no new safety findings. The data will be presented at a forthcoming medical meeting and shared with regulatory authorities.

07:31 EST investor group sends letter to Terran Orbital board regarding meeting request - A group of concerned investors in Terran Orbital comprised of Sophis Investments, Roark's Drift and Tyvak Nano-Satellite Systems' co-founders, Jordi Puig-Suari, Roland Coelho and Austin Williams, together with certain affiliates, which owns approximately 8.4% of the company's common stock, sent a third request to the company's board of directors to discuss protecting and optimizing long-term shareholder value. After repeated attempts, the investor group relayed another message to encourage constructive dialogue with the board regarding opportunities to enhance shareholder value, including, separating the roles of chairman and CEO and hiring a new CEO with demonstrable industry experience and credibility, reconstituting the board and instituting corporate governance practices, and conducting a strategic review process. The full text of the letter follows: "...As our goal remains to protect and maximize the material value we believe is embedded within Terran, we are following up on our previously unanswered correspondence addressed to Terran's Board of Directors (the "Board") dated October 11, 2023 and October 15, 2023. The Concerned Investor Group is the Company's largest independent shareholder and is comprised of co-founders of the Company who have a demonstrable, intimate understanding of Terran, deep industry expertise relevant to its business, and who are committed to helping the Company realize its full potential. Despite the statements made by the Company during its Virtual Town Hall held on October 26, 2023 and in its October 19, 2023 open letter to shareholders that it welcomes and considers shareholder feedback, the Board has ignored our multiple requests for a meeting. Moreover, the Board has seemingly dismissed out of hand the proposals outlined in our letter dated October 11, 2023 regarding opportunities to enhance shareholder value, including (i) separating the roles of Chairman and CEO and hiring a new CEO with demonstrable industry experience and credibility, (ii) reconstituting the Board and instituting best-in-class corporate governance practices, and (iii) conducting a strategic review process. It is simply unacceptable that the Board has refused to meet with us and rather has decided to adopt a seemingly hostile and dismissive attitude toward us as shareholders. We believe such a stance only further erodes shareholder value and market confidence in Terran. Based on our due diligence, we anticipate that the Company will report FY2023 revenue of approximately $143 million, materially below Company guidance of $250 million provided throughout the year.1 Our reduced revenue projection is based on the revenue shortfall due to the delays in customer activity referenced in the Company's September 20, 2023 prospectus and again during the October 26, 2023 Virtual Town Hall. Make no mistake: a 43% miss vs. revenue guidance, with less than eight weeks to go in the year and without proactively providing investors with an interim update, raises major concerns while continuing to call into question the Board and management's credibility. Furthermore, in light of the Company's cash burn rate, treating such a large miss nonchalantly or unduly relying on prospective new orders or delinquent customer payments to materialize is, in our view, a reckless gamble with shareholders' capital. As of the date of this letter, Terran's stock price is down over 40% since September 18, 2023 following its latest dilutive capital raise,2 remains below $1 despite announcing ~$160 million in new orders in recent weeks, and is at risk of being delisted by the New York Stock Exchange. The Board can no longer ignore what we believe the market clearly knows: there are major issues that need to be addressed at the Company. Enclosed is our updated financial addendum, reflecting our revised financial projections described above. Our projections incorporate the recent subcontract award from Lockheed Martin for the Tranche 2 beta contract announced on October 24, 2023; and also account for the impact of certain potential new orders that we believe our CEO candidate can deliver; while discounting the Company's largest (currently insufficiently funded) backlogged order, which would provide incremental upside..."

07:29 EST Century Aluminum, USW ratify new five-year collective bargaining agreement - Century Aluminum Sebree, a wholly owned subsidiary of Century Aluminum Company, announced that a new, five-year collective bargaining agreement with the United Steelworkers Local 9443-00 was ratified on November 8th, 2023, for the Century Sebree aluminum smelter in Robards, KY. The agreement is effective immediately and runs through October 28, 2028, covering approximately 460 hourly workers at the Century Sebree plant. "We are pleased to reach a new agreement with the Steelworkers," said Jesse Gary, Century's President and Chief Executive Officer. "I want to personally thank the leadership of the USW and our employees who worked diligently to reach a fair deal. This collaboration between the two parties exemplifies our ongoing commitment to enhancing opportunities for our employees while simultaneously strengthening Sebree's position in the highly competitive aluminum market."

07:28 EST Climb Global announces authorized GitLab distributor partnership - Climb Channel Solutions (CLMB) wholly owned subsidiary of Climb Global Solutions, announced it has signed an authorized GitLab distributor partnership agreement, enabling Climb to distribute GitLab (GTLB) to authorized resellers. Climb Channel Solutions' portfolio now includes GitLab's comprehensive AI-powered DevSecOps Platform. This distributorship aims to streamline software development processes, enhance team collaboration, and propel businesses toward greater efficiency and innovation. Through this partnership, Climb Channel Solutions will help customers simplify complex development tasks and bolster the integration of security, monitoring, and compliance directly into the development workflow. "We are excited to embark on this journey with GitLab," said Dale Foster, CEO of Climb Channel Solutions. "GitLab's DevSecOps platform is a testament to innovation, and this partnership aligns perfectly with our mission to equip our clients with the best emerging and disruptive technology. Together, we will empower organizations to navigate the ever-evolving landscape of software development and delivery."

07:20 EST Sharecare appoints Brent Layton as CEO - Sharecare announced, in conjunction with its third quarter 2023 financial results, board member Brent Layton will succeed Jeff Arnold as CEO. Formerly president and COO of Centene Corporation, Layton will assume the CEO role at Sharecare on January 2, 2024, and remain on the board. Arnold will transition to the role of executive chairman at that time, remaining active in the business day-to-day and working closely with Brent, focusing on driving the overall strategy of the company, product innovation, addressing market needs with next generation technology such as generative AI, and supporting strategic growth opportunities.

07:19 EST TransDigm declares special cash dividend of $35.00 per share - The record date for the special dividend is November 20, 2023, and the payment date for the dividend is November 27, 2023.

07:17 EST Oatly Group discontinues construction of new production facility - Following certain events after the end of the reporting period, the Company decided to discontinue the construction of its new production facilities in the EMEA and Americas segments. In the fourth quarter of 2023, the Company expects to incur non-cash impairment charges in the range of $110 to $150 million. The Company also expects to incur restructuring and other exit costs of approximately $40 to $50 million relating to these production facilities. The Company currently estimates these restructuring and other exit costs to result in no more than $20 million of net cash outflows over the next two fiscal years, after taking into consideration anticipated proceeds from selling certain equipment. The decision is expected to increase operational focus, reduce complexity, and reduce the Company's capital expenditure requirements, all of which increases management's confidence in the Company's longer-term margin targets.

07:12 EST iKena Oncology shares initial dose escalation data from IK-930 Phase 1 trial - Ikena Oncology announced financial results for the quarter ended September 30, 2023, and provided a corporate update. The Company also shared initial data from twenty-six patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor. IK-930 Dose Escalation Summary and Emerging Proof of Concept in EHE: IK-930 selectively binds TEAD1 and broadly represses oncogenic TEAD signaling as a potent Hippo-pathway inhibitor, a known suppressor pathway in cancers such as epithelioid hemangioendothelioma, mesothelioma, meningioma, and others. IK-930's differentiated paralog selectivity and robust repressor activity in complex with VGLL4 are key characteristics supporting anti-tumor effect in preclinical models. IK-930 is designed to circumvent renal toxicity, potentially resulting in an optimized therapeutic index. Twenty-six patients with a range of solid tumors were treated in the dose escalation portion of the study as of October 31, 2023. The most common tumor type enrolled was EHE. Differentiated Safety Profile: 26 patients have been treated with IK-930 in dose escalation as of October 31, 2023; IK-930 is in the final stages of dose optimization; the tolerability profile observed thus far supports the hypothesis that IK-930's selectivity could provide a wider therapeutic index for this new class of compounds; Proteinuria is an adverse effect of special interest as it may be an on-target effect of broad TEAD inhibition; Treatment-related proteinuria was recorded in 3 out of 26 dose escalation patients and was limited to grade 1-2; The observed proteinuria did not result in dose reduction or treatment interruption; no proteinuria events were considered dose-limiting and in all cases was fully reversible. Other safety observations include: Frequent adverse events to date have been low-grade nausea, fatigue, and diarrhea, and have not required any dose reduction; Two EHE patients with significant liver metastases experienced reversible liver enzyme elevation; One of these patients developed treatment-related grade 3 elevation, deemed dose limiting, and the patient remains on study after dose adjustment; The other patient experienced grade 3-4 elevation that was deemed possibly treatment related; Dose escalation is currently ongoing; 15 patients were treated with doses within the projected efficacious exposure range and pharmacokinetic data showed some variability; 7 out of 15 patients were determined to reach efficacious exposure; Target engagement in tumor, as determined by decreased TEAD gene signature, has been demonstrated in the efficacious dose range; To minimize IK-930 exposure variability, a next generation formulation is now being evaluated in the dose escalation; Recommended dosing for the next stage of the IK-930 program is expected to be determined in the near-term. Emerging Proof of Concept in EHE: Epithelioid hemangioendothelioma is a rare vascular sarcoma defined by gene fusions of either YAP or TAZ genes in the Hippo pathway with other transcriptional regulators. EHE is a slow-growing, invasive tumor with no approved treatment options and is challenging to measure due to diffuse infiltration of multiple organs. It can occur in multiple areas of the body, including the liver, lungs, bones, and blood vessels. People with EHE suffer symptoms that relentlessly affect their quality of life and are consistent with the site of the EHE growth, including liver failure, respiratory issues, and gastrointestinal symptoms, which are frequently accompanied by severe pain across the body. With no approved standard of care, there is substantial need for innovative treatments that can provide clinical benefit and symptom relief and slow or limit the progression of disease. Seven patients with EHE have been treated with IK-930 in the dose escalation portion of the trial; 7 out of 7 EHE patients reached stable disease as a best response so far as measured by RECIST; 3 out of the 7 patients experienced tumor shrinkage in multiple target and non-target lesions; 4 out of 7 highly symptomatic EHE patients enrolled across multiple dose levels reported symptomatic improvement and subjective improvement of quality of life such as improved energy, weight gain, and pain control; 3 out of the 7 patients continue on treatment with time on treatment ranging from 18 to 26 weeks and ongoing; As a result of these initial tolerability and antitumor activity findings, enrollment in the dose escalation phase continues to progress in targeted populations including mesothelioma and meningioma, in addition to EHE; Based on preclinical data indicating IK-930 synergy with EGFR inhibitors to combat therapeutic resistance, a combination cohort for IK-930 and osimertinib in patients with EGFR-mutant non-small cell lung cancer is planned to initiate in 2024.

07:07 EST Canadian Solar announces 5 GW Solar Wafer facility in Thailand - Canadian Solar announced that it is establishing a 5 GW solar PV wafer production facility in Chonburi, Thailand. Canadian Solar is building a state-of-the-art solar photovoltaic N-type wafer manufacturing plant with an annual output of 5 GW, which is slated to begin production in March 2024. The solar wafers produced at this facility will initially be used at the existing Thailand TOPCon cell manufacturing plant in the same location. From 2025 onwards and once the previously announced 5 GW U.S. cell factory in Jeffersonville, Indiana, becomes fully operational, these wafers will be used as inputs to the Indiana cell factory. Highlighting the importance of this new facility, Thomas Koerner, Senior Vice President of Canadian Solar, said, "Establishing this solar wafer factory in Thailand is a key milestone that will enable us to better serve our U.S. customers with a more diversified and resilient supply chain, complementing our recently announced investments in the U.S. in solar cell and solar module manufacturing. Importantly, it will also allow us to responsibly meet the new requirements related to the latest and adjusted AD/CVD ruling by the U.S. Department of Commerce."

07:06 EST Sylvamo announces elimination of approximately 150 positions, 7% of workforce -

07:05 EST Oncolytics reports 'positive' interim results from Phase 1/2 GOBLET study - Oncolytics Biotech announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal by Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial, in an oral presentation at the 2nd International Multidisciplinary Anal Cancer Conference 2023, taking place in Rome, Italy. "The positive interim data from the anal cancer cohort of the Phase 2 GOBLET study presented today at the IMACC meeting is very exciting for our company and the potential of pelareorep in gastrointestinal cancers. These results met the pre-specified success criteria for the cohort and exceeded the results from historical controls in similar patient populations1-7," said Dr. Matt Coffey, President and CEO of Oncolytics. "I am especially pleased to note that this is the third indication from the GOBLET study in a row to meet its success criteria and the fourth indication combining pelareorep and atezolizumab to present positive data, further validating the potential clinical benefit of this combination and opening the door to another potential registrational pathway for pelareorep. Furthermore, we've seen another complete response in an indication where checkpoint inhibitor therapy alone has had limited success historically, which bodes well for the potential of pelareorep to work synergistically with multiple immunotherapies in multiple tumor types." Dr. Arnold commented, "Current treatment options for SCCA are poor, with no defined standard of care for patients who have progressed after first-line therapy. Oncolytics is developing a solid compendium of clinical data showing consistent positive results from the combination of pelareorep and the checkpoint inhibitor atezolizumab. We are particularly pleased by the promising data presented today because they show that pelareorep may have the potential to offer the hope of a new, effective treatment option for patients with advanced SCCA."

07:02 EST Synlogic expects cash to fund operations into 1H25 - Based upon its current operating plan and inclusive of the net cash proceeds from the October financing and milestone payment from Roche, Synlogic expects to have sufficient cash to be able to fund operations further into the first half of 2025.

06:54 EST Enviva appoints CFO Glenn Nunziata as interim CEO - Enviva has appointed Glenn Nunziata as interim CEO in addition to his role as CFO, succeeding Thomas Meth, who has served as CEO since November 2022. Meth will remain President and will focus his time on renegotiating existing customer contracts with the intent of improving Enviva's profitability and returning the business to one that generates the majority of its cash flow from predictable, profitable take-or-pay contracts. Mark Coscio, Enviva's Chief Development Officer, will assume the role of COO, and will continue to lead the company's growth projects while taking on responsibility for plant and port operations. These leadership changes are effective as of November 9.

06:42 EST Oncolytics provides update on pancreatic cancer program for pelareorep - Oncolytics provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma, or PDAC. Oncolytics' collaborator, The Pancreatic Cancer Action Network, or PanCAN, a pancreatic cancer patient advocacy organization, advised the company that it is implementing a strategic re-evaluation of the Precision Promise program and will not be adding any new investigational therapies to the platform until the re-evaluation is complete. Oncolytics and PanCAN had previously planned to initiate a Phase 3 trial using the Precision PromiseSM platform in H1 2024. Oncolytics now plans to conduct an adaptive Phase 3 program of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab, similar to the Precision Promise study and manage it directly within our Clinical Group and a contract research organization, or CRO, with the goal of enrolling the first patient in mid-2024. Additionally, Oncolytics and PanCAN confirmed that PanCAN will continue with its plans to grant US$5 million to Oncolytics as part of the Therapeutic Accelerator Award for the new Phase 2 GOBLET study arm evaluating the combination of pelareorep and modified Folfirinox in pancreatic cancer patients.

06:37 EST NexGen Energy receives Ministerial approval for Rook I Project - NexGen Energy announced that it has received Ministerial approval under The Environmental Assessment Act of Saskatchewan to proceed with the development of its 100%-owned Rook I Project. NexGen is the first company in more than 20 years to receive full Provincial Environmental Assessment approval for a uranium project in Saskatchewan.

06:28 EST Becton Dickinson increases quarterly dividend 4.4% to 95c per share - The board of directors of Becton Dickinson has declared a quarterly dividend of 95c per common share, an increase of 4.4% from the previous quarter. The dividend will be payable on December 29 to holders of record on December 8. The indicated annual dividend rate for FY24 is $3.80 per share.

06:25 EST AstraZeneca announces results from EMERALD-1 Phase III trial of Imfinzi - Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca's Imfinzi in combination with transarterial chemoembolisation, TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival, PFS, versus TACE alone in patients with hepatocellular carcinoma, HCC, eligible for embolisation. The trial continues to follow the secondary endpoint of overall survival, OS. Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "These positive results for Imfinzi-based treatment in EMERALD-1 may bring the potential of immunotherapy to patients with earlier stages of liver cancer. We look forward to discussing these data with regulatory authorities and seeing the survival data mature over time, which will be important as we aim to bring this novel treatment option to patients." The safety profiles for Imfinzi and TACE plus bevacizumab were consistent with the known profile of each medicine, and there were no new safety findings. The data will be presented at a forthcoming medical meeting and shared with regulatory authorities.

06:19 EST TransDigm to acquire Electron Device Business of CPI for $1.39B in cash - TransDigm announced it has entered into a definitive agreement to acquire the Electron Device Business of Communications & Power Industries, or CPI, a portfolio company of TJC, L.P., for approximately $1.39B in cash. Approximately 70% of its revenue is derived from the aftermarket and nearly all of its revenue is generated from proprietary products. CPI's Electron Device Business generated approximately $300M in revenue for its fiscal year ended September 30. The company has manufacturing locations in Palo Alto, California; Beverly, Massachusetts; Middlesex, UK; and Woodland, California. The company employs approximately 900 people. The acquisition, which is expected to close by the end of TransDigm's third fiscal quarter of 2024, is subject to regulatory approvals in the United States and United Kingdom and customary closing conditions. The acquisition is expected to be financed through existing cash on hand as well as new long-term debt.

06:14 EST KBR awarded FFED contract by Fidelis New Energy for Project Fyrkat - KBR announced it has been awarded a Front-End Engineering Design, or FFED, contract by Fidelis New Energy for Project Fyrkat, a liquid carbon dioxide, or LCO2, receiving terminal at the Port of Aalborg, Denmark. Under the terms of the contract, KBR will provide engineering to support the LCO2 handling and storage facility, as Fidelis New Energy aims to help global decarbonization. Project Fyrkat is one of the first onshore CO2 sequestration facilities, and is part of a larger initiative, Project Norne, which expects to store more than 20M tons of CO2 per year by 2030. This equates to around half of all Denmark's yearly emissions. Norne will provide emitting companies with access to an affordable and safe pathway to process their CO2 emissions.

06:07 EST National Vision announces incremental expense reduction program - The company has announced that beginning in 2024, it will be implementing an incremental expense reduction program targeting annualized savings in the range of $10M-$12M. The program will focus on streamlining corporate overhead including optimizing non-customer facing labor costs, as well as reducing travel expenses and third-party spend. This program, together with the expected benefits from non-headline pricing actions the company is planning to take, is expected to more than offset the profitability gap created by the termination of the Walmart (WMT) partnership.

05:27 EST ASE Technology reports October revenue $1.75B, down 13.9% - Reports October ATM revenue $881M, down 16%.

05:18 EST Jacobs, PA Consulting selected by Copenhagen Metro for advisory services - Jacobs and PA Consulting have been selected by The Copenhagen Metro to be part of its Operations and Maintenance Adviser Framework. The Copenhagen Metro provides fast, sustainable, carbon-efficient transport solutions to more than 300,000 passengers on weekdays. The Jacobs and PA team was selected to provide comprehensive research and advice on the operation and maintenance of the metro. Wide-ranging strategic and technical advice will span project and design management, railway installations and safety, rolling stock, and signaling systems, as well as operation and maintenance. The Copenhagen Metro expects the framework to run over an eight-year period.